T1	Premise 42 128	A 58-year-old woman comes for a follow-up visit for diabetes mellitus and hypertension
T2	Premise 130 217	She feels well but states that she has stopped taking verapamil because of constipation
T3	Treatment 184 193	verapamil
T4	Marker 194 201	because
T5	Disease 205 217	constipation
T6	Premise 219 282	She presents with intolerance to ACE inhibitors due to coughing
T7	Premise 284 330	On examination, blood pressure is 156/92 mm Hg
T8	Premise 332 457	CBC includes a creatinine of 1.6 mg/dL, 24-hour urine protein excretion of 1.5 g/day, and a creatinine clearance of 45 ml/min
T9	Disease 552 579	type 2 diabetic nephropathy
T10	Claim 584 623	Angiotensin converting enzyme inhibitor
T11	Claim 628 656	Angiotensin receptor blocker
T12	Claim 661 680	Calcium antagonist.
T13	Claim 684 697	Alpha-blocker
T14	Claim 702 714	Beta-blocker
T15	Treatment 584 624	Angiotensin converting enzyme inhibitor.
T16	Treatment 628 656	Angiotensin receptor blocker
T17	Treatment 661 679	Calcium antagonist
T18	Treatment 684 697	Alpha-blocker
T19	Treatment 702 714	Beta-blocker
T20	Disease 850 870	diabetic nephropathy
T21	Treatment 252 266	ACE inhibitors
T22	Claim 775 904	The antihypertensive drugs that have been shown to slow the progression of diabetic nephropathy are the ACE inhibitors and ARAIIs
T23	Claim 906 1119	Specifically, angiotensin II receptor blockers have demonstrated their efficacy in this field for type 2 DM, which together with the side effects that IECAS produce in the patient makes an ARAII the drug of choice
T24	Disease 1004 1013	type 2 DM
T25	Treatment 920 952	angiotensin II receptor blockers
T26	Treatment 1057 1062	IECAS
T27	Treatment 1095 1100	ARAII
R1	Support Ent1:T23 Ent2:T11	
R2	Support Ent1:T6 Ent2:T23	
T28	Treatment 879 904	ACE inhibitors and ARAIIs
